Antibody Therapeutics (SARS-CoV-2)
COVID-19
Discovery/PreclinicalActive
Key Facts
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage company on a mission to harness the adaptive immune system as a natural diagnostic and therapeutic tool. Its core achievement is the development of the Immune Medicine Platform, which sequences and maps immune receptors at scale, enabling both its growing clonoSEQ MRD diagnostics business and a deep drug discovery pipeline. The company's strategy is to leverage its unique, data-generating platform to create a sustainable competitive moat across both diagnostics and therapeutics, aiming to transform the detection, monitoring, and treatment of disease.
View full company profileOther COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |